Selank showed efficacy and possible mechanisms of action in the therapy of generalized anxiety disorders and neurasthenia.
Selank
Anxiolytic peptide for stress reduction and immune modulation

Overview
Last reviewed: 2026-08-18
Identity & Aliases
Also known as
Status: Research compound - Anxiolytic peptide (approved in Russia)
Full composition (formula, molecular weight, sequence) in Quick Facts →
Research Areas
Available Evidence
Russian clinical studies report anxiolytic efficacy of Selank in generalized anxiety disorder and neurasthenia, with tolerability comparable to the benzodiazepine phenazepam in a comparative study; the trials are small and published in Russian-language journals.
Rodent studies show anxiolytic-like effects and modulation of GABAergic and monoaminergic systems; Selank also displays immunomodulatory activity.
Laboratory studies indicate Selank affects GABA-A receptor function/expression and modulates neuropeptide metabolism; the precise molecular mechanism is not fully established.
The exact mechanism of anxiolysis is unresolved; clinical data come mainly from Russian-language studies with limited international replication, and there is no FDA-approved use.
Key Studies & Findings
Comparative study found the anxiolytic effect and tolerability of Selank comparable to phenazepam in anxiety disorders.
Benefits & Effects
Anti-anxiety
Nootropic
Improves focus
Immunomodulation.
Anxiolytic effects comparable to benzodiazepines
39.6% reduction in morphine withdrawal syndrome
Memory protection via BDNF regulation
No dependence potential
Anti-anxiety
Nootropic
Improves focus
Immunomodulation.
Side Effects & Safety
Minimal side effects
No dependence or memory impairment (unlike benzodiazepines)
Mild side effect
Onset: Minutes-hours
Management: Avoid driving initially; dose adjustment
Dose-dependent
Moderate side effect
Onset: Chronic use
Management: Evaluation needed; sold without adequate safety study
Limitations & Open Questions
Pharmacology
Reported Research Dosing
Reported values from research literature and community protocols. Educational reference only — not a dosing recommendation or medical advice.
200-400 mcg Daily
Research Protocols
Mild anxiety relief
- Dose
- 250mcg daily
- Frequency
- Once daily
- Route
- SubQ injection
Moderate anxiety/cognitive enhancement
- Dose
- 250mcg twice daily
- Frequency
- Morning and evening
- Route
- SubQ injection
Intensive anxiety/stress management
- Dose
- 500mcg daily
- Frequency
- Divided doses
- Route
- SubQ injection
Cognitive enhancement/nootropic use
- Dose
- 250-350mcg daily
- Frequency
- Morning only
- Route
- SubQ injection
PTSD/trauma support
- Dose
- 250mcg twice daily
- Frequency
- Consistent timing
- Route
- SubQ injection
Immune support during stress
- Dose
- 250mcg daily
- Frequency
- Once daily for 2-4 weeks
- Route
- SubQ injection
Research protocols are for educational purposes only. Always consult qualified medical professionals.
Frequently Asked Questions
Is Selank approved by the FDA?
No. It is not FDA-approved; it has been studied in Russia, where it has been used clinically for anxiety, but international regulatory approval is lacking.
How is Selank taken?
In clinical studies it is typically given intranasally; research products are also sold for laboratory use, with no standardized approved dosing.
Research Citations
Povarov IS, Kondratenko RV, Derevyagin VI, Myasoedov NF, Skrebitsky VG (2017)
Konstantinopolsky MA, Chernyakova IV, Kolik LG (2022)
Kolik LG, Nadorova AV, Antipova TA, Kruglov SV, Kudrin VS, Durnev AD (2019)
Fomenko EV, Bobyntsev II, Ivanov AV, Belykh AE, Andreeva LA, Myasoedov NF (2019)
Leonidovna YA, Aleksandrovna SM, Aleksandrovna TA, Aleksandrovna BO, Fedorovich MN, Aleksandrovna AL (2021)
+ 20 more citations
Related Resources
Quick Facts
Formula
C33H57N11O9
Molecular Weight
751.87
Sequence
Thr-Lys-Pro-Arg-Pro-Gly-Pro
Mechanism
Anxiolytic peptide with cognitive enhancement properties
Safety Information
Research compound only in most countries. Limited long-term safety data available.
Citations
25Povarov IS, Kondratenko RV, Derevyagin VI, Myasoedov NF, Skrebitsky VG (2017)
Konstantinopolsky MA, Chernyakova IV, Kolik LG (2022)
Kolik LG, Nadorova AV, Antipova TA, Kruglov SV, Kudrin VS, Durnev AD (2019)
Fomenko EV, Bobyntsev II, Ivanov AV, Belykh AE, Andreeva LA, Myasoedov NF (2019)
Leonidovna YA, Aleksandrovna SM, Aleksandrovna TA, Aleksandrovna BO, Fedorovich MN, Aleksandrovna AL (2021)
+ 20 more citations